No Clinically Significant Interaction Between Famotidine and Buspirone
Famotidine and buspirone can be safely co-administered without dose adjustment, as there is no clinically significant pharmacokinetic or pharmacodynamic interaction between these medications.
Pharmacokinetic Evidence
The FDA drug label for buspirone 1 provides comprehensive documentation of drug interactions, listing specific agents that affect buspirone metabolism through CYP3A4 inhibition or induction. Famotidine is notably absent from this extensive list of interacting medications. The label specifically documents interactions with:
- Strong CYP3A4 inhibitors (itraconazole, nefazodone, ketoconazole, ritonavir) that dramatically increase buspirone levels (up to 19-fold)
- Moderate CYP3A4 inhibitors (erythromycin, diltiazem, verapamil) that increase buspirone 3-6 fold
- CYP3A4 inducers (rifampin) that decrease buspirone levels by ~90%
The FDA label for famotidine 2 confirms that famotidine is only a weak CYP1A2 inhibitor and does not affect CYP3A4, which is the primary metabolic pathway for buspirone 1.
Direct Interaction Study
A specific pharmacokinetic study examined the interaction between cimetidine (a structurally related H2-blocker) and buspirone 3. This 1987 study in 10 healthy volunteers found no clinically significant interaction between cimetidine and buspirone, with only a minor 31% increase in the active metabolite 1-PP that was not clinically meaningful. Since famotidine has even less potential for drug interactions than cimetidine 4, 5, this further supports the safety of combining famotidine with buspirone.
Mechanism-Based Safety
Famotidine's pharmacologic profile makes interaction unlikely:
- Famotidine is primarily renally eliminated (65-70% unchanged) 2, 6
- It undergoes minimal hepatic metabolism 2
- It does not interact with the cytochrome P450 system 4, 5
- It is a substrate for OAT1/OAT3 and inhibits MATE-1, but these pathways are irrelevant to buspirone metabolism 2
Buspirone is metabolized via CYP3A4 1, a pathway that famotidine does not affect.
Clinical Recommendation
No dose adjustment is necessary when co-prescribing famotidine and buspirone. Standard dosing of both medications can be used safely. The population pharmacokinetic study of atogepant 7 specifically confirmed that famotidine co-administration had no clinically relevant effect on drug pharmacokinetics, demonstrating famotidine's minimal interaction potential in real-world settings.
Important Caveat
While famotidine itself poses no interaction risk, clinicians should remain vigilant about other medications the patient may be taking that DO interact with buspirone, particularly CYP3A4 inhibitors (azole antifungals, macrolide antibiotics, calcium channel blockers) or inducers (rifampin, anticonvulsants) 1.